Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost
South Africa
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
Created on
April 29, 2024
Last modified
April 29, 2024
Page views
24591
Download
2
Documentation in PDF
Metadata
DDI/XML
JSON
- Data files
- SHERPA_Safetydata
art_drug_1 (art_drug_1)
Data file: SHERPA_Safetydata
Overview
Valid:
343
Invalid:
0
Type:
Discrete
Width:
45
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| 3TC | 1 |
0.3%
|
|
| 3TC/EFV | 1 |
0.3%
|
|
| ABACAVIR | 1 |
0.3%
|
|
| ABC | 3 |
0.9%
|
|
| ALLUVIA | 1 |
0.3%
|
|
| ATROIZA | 1 |
0.3%
|
|
| ATROZIA | 1 |
0.3%
|
|
| AZT | 1 |
0.3%
|
|
| AZT/3TC | 2 |
0.6%
|
|
| Abacavir | 2 |
0.6%
|
|
| Abacavir; Emtricitibine; Efavirenz | 1 |
0.3%
|
|
| Acriptega | 20 |
5.8%
|
|
| Adurant | 1 |
0.3%
|
|
| Alluvia | 14 |
4.1%
|
|
| Alluvia + Tenemine(TDR;FTC;LPV/r) | 1 |
0.3%
|
|
| Alluvia 2 bd | 1 |
0.3%
|
|
| Aluiva | 1 |
0.3%
|
|
| Aluvia | 13 |
3.8%
|
|
| Aluvia (Lopinavir 400mg, Ritonavir 100mg) | 3 |
0.9%
|
|
| Aluvia Tabs | 1 |
0.3%
|
|
| Anteretroviral Medication Unknown | 1 |
0.3%
|
|
| Aroiza | 1 |
0.3%
|
|
| Atazanavir | 1 |
0.3%
|
|
| Atazanavir/Ritonavir | 1 |
0.3%
|
|
| Atazor | 1 |
0.3%
|
|
| Atenef | 1 |
0.3%
|
|
| Atrioza | 1 |
0.3%
|
|
| Atripla | 2 |
0.6%
|
|
| Atroiza | 48 |
14%
|
|
| Atroiza (efavirenz/tenofovirDF/emtricitabin) | 5 |
1.5%
|
|
| DK | 2 |
0.6%
|
|
| DUMIVA | 1 |
0.3%
|
|
| Dolutegravir | 1 |
0.3%
|
|
| Dolutegravir (DTG) | 1 |
0.3%
|
|
| Dumiva | 4 |
1.2%
|
|
| Efavirenz | 1 |
0.3%
|
|
| Emtroc | 1 |
0.3%
|
|
| FDC | 1 |
0.3%
|
|
| FDC (UNCERTAIN OF REGIMEN NAME) | 1 |
0.3%
|
|
| FDC (efavirenz/tenofovirDF/emtricitabin) | 1 |
0.3%
|
|
| FDC with Dolutegravir or Efavirenz | 1 |
0.3%
|
|
| Heftenam | 2 |
0.6%
|
|
| Heftenam (efavirenz) | 1 |
0.3%
|
|
| Heteruam | 1 |
0.3%
|
|
| LAMZID | 1 |
0.3%
|
|
| LTD | 1 |
0.3%
|
|
| Lamivudine | 1 |
0.3%
|
|
| Lamivudine/Zidovudine | 1 |
0.3%
|
|
| Lamzid | 2 |
0.6%
|
|
| Lamzid + aluvia | 1 |
0.3%
|
|
| Lamzid A | 1 |
0.3%
|
|
| Luvigen | 17 |
5%
|
|
| Name of ART drug unknown | 1 |
0.3%
|
|
| Nevarapine | 2 |
0.6%
|
|
| Nevirepine | 1 |
0.3%
|
|
| Odimne | 1 |
0.3%
|
|
| Odimune | 18 |
5.2%
|
|
| Odimune (efavirenz, FTC, tenofovir) | 8 |
2.3%
|
|
| PATIENT UNSURE OF DRUG NAME (NEWLY DIAGNOSED) | 1 |
0.3%
|
|
| Prep | 1 |
0.3%
|
|
| Ranega | 1 |
0.3%
|
|
| Reydin | 2 |
0.6%
|
|
| TDF | 1 |
0.3%
|
|
| TDF/3TC | 1 |
0.3%
|
|
| TDF/AZT OD | 1 |
0.3%
|
|
| TEE | 1 |
0.3%
|
|
| TENOFOVIR | 2 |
0.6%
|
|
| TLD | 7 |
2%
|
|
| TRUVADA | 1 |
0.3%
|
|
| TRUVADA (PREP) | 1 |
0.3%
|
|
| Teevir Tabs | 1 |
0.3%
|
|
| Telatri | 2 |
0.6%
|
|
| Tenefovir 300mg | 2 |
0.6%
|
|
| Tenemine | 4 |
1.2%
|
|
| Tenofovir | 3 |
0.9%
|
|
| Tenofovir 300mg | 1 |
0.3%
|
|
| Tenofovir, Lamivudine, Dolutegravir | 2 |
0.6%
|
|
| Tribuss | 16 |
4.7%
|
|
| Tribuss (efavirenz, FTC and tenofovir) | 1 |
0.3%
|
|
| Trivenz | 3 |
0.9%
|
|
| Trivir | 1 |
0.3%
|
|
| Truvada | 8 |
2.3%
|
|
| Truvada (for Hep B) | 1 |
0.3%
|
|
| Truvada - PreP | 2 |
0.6%
|
|
| UNKNOWN | 1 |
0.3%
|
|
| Unknown | 24 |
7%
|
|
| Unknown 2 tablets | 1 |
0.3%
|
|
| Unkown | 1 |
0.3%
|
|
| Viropon tablets | 1 |
0.3%
|
|
| Vulante | 1 |
0.3%
|
|
| ZOVILAM | 1 |
0.3%
|
|
| Zidovudine | 5 |
1.5%
|
|
| Zidovudine/Lamivudine | 2 |
0.6%
|
|
| Zovilam | 1 |
0.3%
|
|
| abacavir | 2 |
0.6%
|
|
| acriptega | 1 |
0.3%
|
|
| alluvia | 3 |
0.9%
|
|
| alluvia,TDF,3TC | 1 |
0.3%
|
|
| atroiza | 2 |
0.6%
|
|
| dumiva | 2 |
0.6%
|
|
| dumiva 1 daily | 1 |
0.3%
|
|
| dumivia | 1 |
0.3%
|
|
| emtricitabine | 1 |
0.3%
|
|
| nevirapine | 1 |
0.3%
|
|
| tenofovir DF; emtricitabine (FTC) | 1 |
0.3%
|
|
| tld | 1 |
0.3%
|
|
| tribuss | 8 |
2.3%
|
|
| trivenz | 1 |
0.3%
|
|
| unknown | 2 |
0.6%
|
|
| unknown 2nd line regimen | 1 |
0.3%
|
|
| unknown drugs pre-exposure prophylaxis | 2 |
0.6%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.